Complement mediated renal disease. Tim Goodship Institute of Genetic Medicine Newcastle University
|
|
- Benedict Gray
- 5 years ago
- Views:
Transcription
1 Complement mediated renal disease Tim Goodship Institute of Genetic Medicine Newcastle University
2 Evidence of complement activation is IgA and HSP Membranous Lupus nephritis ANCA associated Anti-GBM MPGN, C3 GN ahus found in
3 Normal Patient Haemolytic uraemic syndrome Microangiopathic hemolytic anaemia Thrombocytopenia Acute renal failure
4 Haemolytic uraemic syndrome Typical STEC HUS 90% - preceding EHEC infection Atypical HUS 10% - Sporadic 9% - Familial 1%
5
6 Newcastle family 2013
7 Exeter family
8 Belgian family 3 affected male siblings All successfully transplanted with no recurrence
9 ahus and linkage to the RCA cluster 1p RCA GENE CLUSTER Factor XIIIb Complement Factor H Factor H related proteins HUS 1q 1q 32 C4bp DAF CR2 CR1 MCP Warwicker et al, KI 1998
10 Classical Lectin Alternative Inflammation (C3a/C5a) C3b Lysis (C5b-C9) Opsonization (C3b/C4b)
11 Complement activation C3 B C3b Bb Cell membrane
12 Complement regulation Factor I C3 B Factor H C3b Bb MCP Cell membrane
13 Factor H functional domains Regulatory Recognition
14 c.351delg c Pro258Leu Factor H mutations in ahus c.1494dela Pro621Thre Ser714stop Val835Leu Glu850Lys Gln950His Tyr951His Thr956Met Ile970Val Cys973Tyr Trp978Cys Val1060Ala Gln1076Glu Glu1172Stop Arg1182Ser c.3546_3581dup36 Trp1183Arg Trp1183Leu Trp1183Phe Trp1183Stop Thr1184Arg Leu1189Arg Leu1189Phe Ser1191Leu Ser1191Trp Gly1194Asp Val1197Ala Glu1198Ala Glu1198Lys Glu1198Stop Phe1199Ser Gly1204Glu Arg1210Cys Arg1215Gly Arg1215 Gln Thr1216 c.3674a>t, c.3675_3699 del Pro1226Ser c.3695_ delAGAA rg53cys rg78gly Glu189Stop Gln400Lys Cys536Arg Cys630Trp Cys673Tyr c.2303_2304dupa Ile881Leu Ser890Ile His893Arg c Tyr899Stop Cys915Ser Gln925Stop Val1007Cys c.3032delg Tyr1021Phe Cys1043Arg Asp1119Gly Val1134Gly Tyr1142Asp Tyr1142Cys Trp1157Arg c.3486dela Cys1163Trp c g>a
15 Inherited and acquired abnormalities of complement are found in up to 70% of ahus patients C3 (5%) C3 Factor B (1%) B Factor I (10%) CFHRs (5%) Factor H (30%) (1%) C3b Bb Thrombomodulin (5%) (10%) CD46 (10%)
16 Newcastle family 2013
17 The RCA (regulation of complement activation) gene cluster has arisen through a series of duplication events
18 Deletion of CFHR3 and CFHR1
19 ~4% of the normal population have no factor related 1 or 3 protein Feifel et al, Immunogenetics 1992 kda Factor H Factor H related 1 kda Factor H Factor H related Factor H related 3 25
20 Deletion of CFHR3 and CFHR1
21 Genomic disorders affecting CFH/CFHRs - macrohomology CFHR3/1 AMD protective ahus predisposition to fh Ab if homozygous SLE predisposes IgA protective CFHR1/4 ahus predisposition to fh Ab CFH/CFHR1 hybrid ahus CFHR1/CFH hybrid ahus
22 Acquired defects Trigger Disease Rare genetic variants Common genetic variants
23 A patient from Belfast Female aged 22 - acute hepatic vein thrombosis (Budd Chiari syndrome). Admitted to liver unit Kings College Hospital London. No underlying abnormality on thrombophilia screen. Cadaver liver transplant successful with no major complications. Maintenance immunosuppression with tacrolimus
24 A patient from Belfast Age 25 Successful pregnancy but 3/52 post partum develops ahus. No recovery of renal function despite PE. C g/l ( ) C g/l ( ) Factor H 0.45 g/l ( ) Factor I 64 mg/l (38 58) CD 46 expression normal Mutation screening of CFH, CFI, CD46, C3, CFB, THBD - negative Factor H and thrombomodulin autoantibodies - negative
25 A patient from Belfast What about the donor? 41 year old female intracranial haemorrhage FBC, CUE and LFTs all normal Urine output of 4.4 litres in the 24 hours No family history Mutation screening of the donor DNA showed a CFH mutation c.1107 G>A; p.trp369stop. Not previously described.
26 Additional susceptibility factors MCP GGAAC
27 Acquired defects Trigger Pregnancy Disease Rare genetic Variants CFH mutant Common genetic variants Homozygous CD46 GGAAC
28 Differential diagnosis of TMA STEC HUS TTP ahus Malignant hypertension Scleroderma APL antibody syndrome SLE HIV Malignancy Cobalamin C disease
29 Investigation of incident patients ADAMTS13 activity to exclude TTP Exclude STEC associated HUS C3, C4, factor H and factor I levels MCP (CD46) expression on PBMCs Mutation screening of CFH, CFI, CD46, CFB, C3 and THBD Identification of genomic disorders deletions and hybrid genes Factor H autoantibodies
30 Stool culture Diagnosis of EHEC associated HUS Serodiagnosis Detection of Stx Polyvalent IgG IgM Chart et al, J Med Microbiol 2002
31 Initial management Recommendations. All patients presenting with ahus should be offered a trial of plasma exchange and/or plasma infusions. (weak, low) Noris et al, CJASN 2010
32 Recurrence post transplant according to underlying gene Mutation Recurrence rate Loss of graft CFH 75-90% 60-90% CFI 45-80% 90% C % 60% CFB 100% 100% CD46 <20% 30%
33 Recurrence post transplant in patients known to have a factor H mutation No Factor H mutations Factor H mutations Bresin et al, CJASN 2006
34 Sibling LRD
35 Developed HUS 3/12 later graft lost to recurrent HUS
36 Liver* and Liver/kidney Tx in ahus Age Reference 1 year survival 2 years Remuzzi, Lancet 2002 Alive 3 months* Cheong, Ped Nephrol 2004 Deceased 2 years Remuzzi, Am J Transplant 2005 Deceased 5 years Saland, Am J Transplant 2006 Alive 1 year Jalanko, Am J Transplant 2007 Alive 16 year Jalanko, Am J Transplant 2007 Alive 4 years Saland, CJASN 2009 Alive Adult Jalanko, Personal communication Alive Adult Sanchez-Corral, Br J Haematol 2010 Alive 4 years* Haller, Am J Transplant 2010 Alive 5 years Milner, Personal communication Alive 12 years Saland, Personal communication Deceased 8 years Saland, Personal communication Deceased Child Cohn, Personal communication Alive 64 years Wilson, Am J Kidney Dis 2011 Alive 1 year patient survival of 74% (88%) cf. primary hyperoxaluria 86% (Jamieson, Am J Nephrol 2005)
37 Gruppo RA, et al. N Engl J Med. 2009;360(5): Patient continues to do well at home (and school) on chronic eculizumab (34 months)
38
39 Cfh +/+ Normal Cfh -/- MPGN Cfh -/- FH HUS Cfh -/-, C5 -/- FH Normal
40 What is the prevalence/incidence of ahus in the UK? Data for all UK renal units At least 177 patients in the UK 139 England 23 Scotland 12 Wales 3 Northern Ireland 49 are under the age of female and 68 male 9 patients undergoing plasma therapy 6 adults and 8 children on eculizumab 62 patients undergoing dialysis 9 are on the transplant list Prevalence of ~ 2.7/million but 5.5/million in North East 2009 and new patients : incidence of 0.25 (0.4)
41 A national ahus service for England Very rare diseases in England are managed through a National Specialised Service PNH is managed through such a service Application considered by the Advisory Group for National Specialised Services in June 2012 referred to NICE If successful Based in Newcastle Shared care service for both paediatric/adults Special investigations (genetics/autoantibodies) Eculizumab administered locally but paid for out of a central budget 24 hr on-call service for advice
42 ahus treatment in the future Incident patients -patient groups Prevalent patients on plasma therapy Prevalent patients on dialysis - transplant Prevalent patients with infrequent relapses Prevalent patients in remission Prevalent patients with a functioning transplant Unaffected carriers
43 ahus treatment in the future Incident patients -patient groups Prevalent patients on plasma therapy Prevalent patients on dialysis - transplant Prevalent patients with infrequent relapses Prevalent patients in remission Prevalent patients with a functioning transplant Unaffected carriers
44 ahus treatment in the future Incident patients -patient groups Prevalent patients on plasma therapy Prevalent patients on dialysis - transplant Prevalent patients with infrequent relapses Prevalent patients in remission Prevalent patients with a functioning transplant Unaffected carriers
45 Treatment of prevalent patients on dialysis- transplant with eculizumab Median follow up of 14.5 months Mean creatinine 72 µmol No recurrence Zuber et al, Am J Transplant 2012
46 ahus treatment in the future Incident patients -patient groups Prevalent patients on plasma therapy Prevalent patients on dialysis - transplant Prevalent patients with infrequent relapses Prevalent patients in remission Prevalent patients with a functioning transplant Unaffected carriers
47 ahus treatment in the future Incident patients -patient groups Prevalent patients on plasma therapy Prevalent patients on dialysis - transplant Prevalent patients with infrequent relapses Prevalent patients in remission Prevalent patients with a functioning transplant Unaffected carriers
48 Lessons from using eculizumab in PNH Meningococcal disease 0.5 events per 100 year 2 deaths with delay in diagnosis/therapy UK, all patients get antibiotics, throat swab Serology post tetravalent vaccine Eculizumab dosage measure levels <50mg/ml susceptible to breakthrough >100mg/ml blocked Pregnancy Does not cross the placenta Higher doses needed No neutralising antibodies detected
49 Drugs costing over $200,000/year Drug Indication Company Soliris (eculizumab) Elaprase (idursulfase) Naglazyme (galsulfase) Cinryze (C1 esterase inhibitor) Myozyme (alglucosidase) Arcalyst (rilonacept) Fabrazyme (agalsidase beta) Cerezyme (imiglucerase) Aldurazyme (laronidase) PNH and ahus Hunter syndrome Maroteaux Lamy syndrome Hereditary angiodema Pompe disease Cryopyrin-associated periodic syndromes Fabry disease Gaucher disease Hurler syndrome Alexion Shire BioMarin ViroPharma ViroPharma Regeneron Genzyme Genzyme Genzyme BioMarin
50 Justification for the cost of drugs such as eculizumab Very small number of patients with PNH and ahus Substantial investment in previous trials using pexelizumab and eculizumab 2142 patients in PRIMO-CABG 5100 patients in APEX-AMI 350 patients in rheumatoid arthritis trial $800m investment before approval for PNH $150m investment in manufacturing $200m investment in rare disease R&D
51 Unresolved issues What is the risk of recurrence if eculizumab is withdrawn? 18 patients have stopped therapy and the disease has relapsed in 5. What are the renal risks of long term therapy? Ongoing C3 deposition. Binding to C5 in renal tissues Herlitz et al, JASN 2012
Recent advances in pathogenesis & treatment of ahus
Recent advances in pathogenesis & treatment of ahus Miquel Blasco Pelicano Nephrology and Kidney Transplant Unit Hospital Clínic, Barcelona Atypical Hemolytic Uremic Syndrome (ahus) Ultra-rare disease:
More informationM.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.
M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic
More informationR. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk
R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy Lindsay Keir Richard
More informationNew insights in thrombotic microangiopathies : TTP and ahus
New insights in thrombotic microangiopathies : TTP and ahus Dr Catherine LAMBERT Hematology Cliniques universitaires Saint-Luc Catherine.lambert@uclouvain.be New insights in thrombotic microangiopathies
More informationThrombotic Microangiopathy (TMA) The Clinical Facets of TMA
International Consensus on Management Atypical Hemolytic Uremic Syndrome in Children Loirat C. et al. Pediatr Nephrol 31: 15-39, 2016 Ruth A. McDonald, MD Professor and Vice Chair Clinical Affairs Department
More informationC3 Glomerulopathy. Jun-Ki Park
C3 Glomerulopathy Jun-Ki Park 03.08.11 For the last 30 years classification MPGN is based on glomerular findings by light microscopy with further specification on EM and staining for Ig and complement
More informationRisk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy
Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris WWA SFH
More informationSpectrum of complement-mediated thrombotic microangiopathies after kidney transplantation
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Marius Miglinas Vilnius university hospital: Nephrology center, Center of Rare Kidney Diseases Vilnius university
More informationHaemolytic uraemic syndrome the story of a whodunit
Haemolytic uraemic syndrome the story of a whodunit Paul Warwicker Lancashire Teaching Hospitals NHS Trust RCP Kidney for the General Physician Conference Nov 17 Renal thrombotic microangiopathy (TMA)
More informationHemolytic uremic syndrome
Hemolytic uremic syndrome Doyeun Oh Department of Internal Medicine CHA University School of Medicine Disclosures for Doyeun Oh Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationUnravelling the pathophysiology of HUS in light of recent discoveries on complement activation
Unravelling the pathophysiology of HUS in light of recent discoveries on complement activation Marina Noris November 13, 2018 1 THROMBOTIC MICROANGIOPATHY Histology lesions: Swelling and detachment of
More informationahus: recent insights and management
ahus: recent insights and management Steven Van Laecke MD, PhD Renal Division, Ghent University Hospital, Belgium 13 th BANTAO Sarajevo October 8 2017 The complement is everywhere I could benefit from
More informationDRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)
Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus
More informationw ahus pathology is linked to dysregulation of the alternative complement pathway.
ahus - Pathogenesis, Etiology, and Clinical Advances Craig B. Langman MD The Isaac A Abt MD Professor of Kidney Diseases Feinberg School of Medicine, Northwestern University Head, Kidney Diseases The Ann
More informationPathogenetic mechanisms in atypical HUS
Pathogenetic mechanisms in atypical HUS Seppo Meri University & University Hospital Helsinki, Finland Antalya, Turkey Photo: Markku Kallio 21.10.2017 HUS after eating Kebab - 22 yo female - watery diarrhea
More informationahus: Facts, Controversies & Treatment Updates Patrick D. Brophy MD Pediatric Nephrology, Dialysis & Transplant University of Iowa
ahus: Facts, Controversies & Treatment Updates Patrick D. Brophy MD Pediatric Nephrology, Dialysis & Transplant University of Iowa DISCLOSURE STATEMENT I, Patrick Brophy disclose the following relationships.
More informationHemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
More informationHUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI
HUS and TTP Testing Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI Disclosures Relevant Financial Relationships Consultant: Ablynx, Bayer, CSL Behring,
More informationSpecialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus)
Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus) Document Author: Assistant Director for Evidence, Evaluation and Effectiveness Executive Lead: Medical Director
More informationRaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable
Alport Syndrome and Type IV collagenopathies APRT Deficiency Alport Syndrome definite or probable Alport carrier definite or probable Thin basement membrane nephropathy APRT Deficiency confirmed Abolished
More informationAtypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Mouhanna Abu Ghanimeh 1, Omar Abughanimeh 1, Ayman Qasrawi 1, Abdulraheem
More informationIntroduction to pathogenesis and treatment of thrombotic microangiopathies (TMA)
Introduction to pathogenesis and treatment of thrombotic microangiopathies (TMA) JM.Campistol, Nephrology and Renal Transplant Department, Hospital Clinic, University of Barcelona, Barcelona, Spain. jmcampis@clinic.cat
More informationTMA CASE STUDY. Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit
TMA CASE STUDY Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit Cumulative fraction of patients free of events ahus is a catastrophic disease that can result in sudden & progressive
More informationAtypical hemolytic uremic syndrome. Diana Karpman Department of Pediatrics Lund University
Atypical hemolytic uremic syndrome Diana Karpman Department of Pediatrics Lund University Image courtesy of Dr. Sabine Leh, Haukeland University Hospital, Bergen Norway Hemolytic Uremic Syndrome Non-immune
More informationEculizumab as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Adult Living-Related Kidney Transplantation
Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living- Related Kidney Transplantation Authors: Miquel Blasco 1, Santiago Rodríguez de Córdoba 2, Fritz Diekmann 1, Mercedes Saiz
More informationComplement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna
Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary
More informationHemolytic Uremic Syndrome
Hemolytic Uremic Syndrome Francesco Emma Division of Nephrology and Dialysis Bambino Gesù Children s Hospital, IRCCS Rome, Italy Hemolytic Uremic Syndrome (HUS) microangiopathic hemolytic anemia thrombocytopenia
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationSacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam
Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research,
More informationECULIZUMAB LONG-TERM THERAPY FOR PEDIATRIC RENAL. Centro de Investigaciones Biológicas - Consejo Superior de Investigaciones
TITLE PAGE ECULIZUMAB LONG-TERM THERAPY FOR PEDIATRIC RENAL TRANSPLANT IN ahus WITH CFH/CFHR1 HYBRID GENE. Román-Ortiz E a *, Mendizabal Oteiza S a, Pinto S b, López-Trascasa M c, Sánchez- Corral P c and
More informationWhat is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
More informationNovel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab
Nephrol Dial Transplant (2014) 29: iv131 iv141 doi: 10.1093/ndt/gfu235 Full Review Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab Jacobien C. Verhave 1, Jack F.M. Wetzels
More informationSupplemental Table 1. Country of origin of the samples collected for the studies included in this systematic review. Authors PubMed ID.
Supplemental Note In order to obtain all articles relevant to this study, key search terms were used in various combinations with the AND operator. Search terms included: pyrazinamide, resistance, Mycobacterium
More informationAcquired Drivers of Disaese ahus and autoantibodies: their role in disease and their impact on patient management
Acquired Drivers of Disaese ahus and autoantibodies: their role in disease and their impact on patient management Veronique Fremeaux-Bacchi Cordeliers Research Center and Européen Georges Pompidou Hospital,
More informationChallenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School
Challenges in Renal Apheresis Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School Outline Principles of Separation ASFA Guidelines Renal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Soliris (eculizumab) Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Soliris (eculizumab) Prime Therapeutics will review Prior Authorization requests
More informationKidney disease associated with autoimmune disease
Kidney disease associated with autoimmune disease Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan M-type Phospholipase A2 Receptor as
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationSoliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
More information1/26/12. Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY OBJECTIVES. Classically Different Topics but not so much
1/26/12 OBJECTIVES Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY Chatchawin Assanasen MD Recognize implications of complement pathway diseases Signs and symptoms of PNH and ahus Complications
More informationC3 GLOMERULOPATHIES. Budapest Nephrology School Zoltan Laszik
C3 GLOMERULOPATHIES Budapest Nephrology School 8.30.2018. Zoltan Laszik 1 Learning Objectives Familiarize with the pathogenetic mechanisms of glomerular diseases Learn the pathologic landscape and clinical
More informationFive papers that influenced my practice. Stephen Marks Consultant Paediatric Nephrologist
Five papers that influenced my practice Stephen Marks Consultant Paediatric Nephrologist Great Ormond Street Hospital for Children and UCL Institute of Child Health, London, UK. Nephrology for the General
More informationFrom MPGN to C3G. F Fakhouri, Nantes, France. «Membranoproliferative» is a pathological feature. Mesangial expansion «Doubles contours»
From MPGN to C3G F Fakhouri, Nantes, France Conflits d intérêt: consultant auprès d Alexion Pharmaceuticals «Membranoproliferative» is a pathological feature Mesangial expansion «Doubles contours» Immune
More informationTMA in HUS and TTP: new insights
TMA in HUS and TTP: new insights Daan Dierickx University Hospitals Leuven, Department of Hematology, Belgium 20th Annual Meeting Belgian Society on Thrombosis and Haemostatis Antwerpen, 22 th November
More informationClinical Commissioning Policy Statement: Eculizumab for atypical haemolytic uraemic syndrome. September 2013 Reference: E03/PS(HSS)/a.
Clinical Commissioning Policy Statement: Eculizumab for atypical haemolytic uraemic syndrome September 2013 Reference: E03/PS(HSS)/a England 1 NHS England INFORMATION READER BOX Directorate Medical Operations
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Eculizumab
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationRaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable
Alport Syndrome and Type IV collagenopathies APRT Deficiency Alport Syndrome definite or probable Alport carrier definite or probable Thin basement membrane nephropathy APRT Deficiency confirmed Abolished
More informationClinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
Hindawi Publishing Corporation Advances in Hematology Volume 214, Article ID 295323, 7 pages http://dx.doi.org/1.1155/214/295323 Clinical Study Therapy Leads to Rapid Resolution of Thrombocytopenia in
More informationThrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics
Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular Genetics Helen Liapis, M.D. Senior Consultant Arkana Labs Professor of Pathology & Immunology. retired Washington University School
More informationLes microangiopathies thrombotiques Quoi de neuf?
Les microangiopathies thrombotiques Quoi de neuf? Société des Sciences Vasculaires du Québec 16 Septembre 2016 Anne-Laure Lapeyraque CHU Sainte Justine, Montréal anne.laure.lapeyraque@umontreal.ca Objectifs
More informationRecurrence of C3G after renal transplantation. Moglie Le Quintrec Service de Néphrologie, Hôpital Foch CRC, UMRS 1138, Equipe complement and diseases
Recurrence of C3G after renal transplantation Moglie Le Quintrec Service de Néphrologie, Hôpital Foch CRC, UMRS 1138, Equipe complement and diseases New MPGN classification C3G MPGN I DDD C3GN IF C3 deposits
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eculizumab_soliris 8/2014 4/2018 4/2019 4/2018 Description of Procedure or Service Paroxysmal nocturnal hemoglobinuria
More informationComplement and the atypical hemolytic uremic syndrome in children
Pediatr Nephrol (2008) 23:1957 1972 DOI 10.1007/s00467-008-0872-4 EDUCATIONAL REVIEW Complement and the atypical hemolytic uremic syndrome in children Chantal Loirat & Marina Noris & Véronique Fremeaux-Bacchi
More informationTherapeutic Complement Intervention Michael Kirschfink, Institute of Immunology, University of Heidelberg, Germany
Therapeutic Complement Intervention Michael Kirschfink, Institute of Immunology, University of Heidelberg, Germany Complement-mediated diseases Therapeutic intervention The complement system is involved
More informationahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.
To learn more about ahus, visit www.ahussource.com ahus A PATIENT S GUIDE Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1169 BECOME EMPOWERED By learning more and taking control
More informationHighly specialised technologies guidance Published: 28 January 2015 nice.org.uk/guidance/hst1
Eculizumab for treating atypical haemolytic uraemic syndrome Highly specialised technologies guidance Published: 28 January 2015 nice.org.uk/guidance/hst1 NICE 2018. All rights reserved. Subject to Notice
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Barry Skikne MD, FACP, FCP(SA) Professor of Hematology Division of Hematologic Malignancies and Cellular Therapeutics Cardinal Clinical Manifestations PNH Clonal disease
More informationAnastasios E. Germenis
Anastasios E. Germenis Professor and Chairman Department of Immunology & Histocompatibility School of Medicine University of Thessaly University Hospital of Larissa Greece agermen@med.uth.gr The Complement
More informationSoliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus)
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus) New Data from the Largest Prospective Trial of Adult Patients
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SP281 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid, 3 Chantal
More informationThrombotic Microangiopathy and the Kidney
CJASN epress. Published on October 17, 2017 as doi: 10.2215/CJN.00620117 Thrombotic Microangiopathy and the Kidney Vicky Brocklebank,* Katrina M. Wood, and David Kavanagh* Abstract Thrombotic microangiopathy
More informationDraft ahus Patients Research Agenda
Important notice this is just a draft. 1. Disease onset Draft ahus Patients Research Agenda ahus Registry ahus Global Poll Rare Disease Day Video How transient is ahus due to pregnancy and is there a role
More informationAtypical IgA Nephropathy
Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA
More informationEculizumab in ahus: where do we stand in Prof. Fadi Fakhouri Dept. of nephrology and immunology, CHU de Nantes.
Eculizumab in ahus: where do we stand in 2016 Prof. Fadi Fakhouri Dept. of nephrology and immunology, CHU de Nantes. INSERM UMR S-1064 Thrombotic microangiopathy: evolving concepts ST-HUS Coagulation mediated-tma
More informationIntroduction. Arif Asif 1 Ali Nayer 2 Christian S. Haas 3
J Nephrol (2017) 30:347 362 DOI 10.1007/s40620-016-0357-7 REVIEW Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment
More informationDiagnosis and Treatment of Common TMAs
Diagnosis and Treatment of Common TMAs K. Pavenski, MD FRCPC St. Michael s Hospital June 13, 2014 Disclosures I have a relevant conflict of interest - Alexion Pharmaceuticals Inc. Participated in advisory
More informationSoliris and You. Your Guide To Living With ahus. INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)
INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children
More informationCan eculizumab be discontinued in ahus? Case report and review of the literature
Clinical Case Report Medicine Can eculizumab be discontinued in ahus? Case report and review of the literature Tuncay Sahutoglu, MD a,, Taner Basturk, MD a, Tamer Sakaci, MD a, Yener Koc, MD a, Elbis Ahbap,
More informationCoding... 5 Benefit Application... 5 Description of Services... 6 Clinical Evidence... 7
TABLE OF CONTENTS Product Variations.... 1 Policy Statement.... 1 Related Policies.... 4 Policy Guidelines..... 4 Coding.... 5 Benefit Application........ 5 Description of Services..... 6 Clinical Evidence.......
More informationUntying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome
REVIEW Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Han-Mou Tsai, MD imah Hematology Associates, New Hyde Park, NY. ABSTRACT Patients presenting with microangiopathic
More informationEvidentiary and Decision Making Challenges in the Context of Rare Diseases Provincial Program Perspective
Evidentiary and Decision Making Challenges in the Context of Rare Diseases Provincial Program Perspective Brent Fraser Director, Drug Program Services Ontario Public Drug Programs Ministry of Health and
More informationTHERAPEUTIC PLASMA EXCHANGE
THERAPEUTIC PLASMA EXCHANGE DIRECTORATE OF NEPHROLOGY AND TRANSPLANTATION Background and Indications Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique in which plasma
More informationSoliris. Soliris (eculizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.11 Subject: Soliris Page: 1 of 5 Last Review Date: September 20, 2018 Soliris Description Soliris
More informationMedication Prior Authorization Form
Policy Number: 1054 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More informationPhysiologie du complément et son implication dans la pathologie rénale
Physiologie du complément et son implication dans la pathologie rénale Veronique Frémeaux-Bacchi Hôpital Européen Georges Pompidou Paris veronique.fremeaux-bacchi@aphp.fr Conflicts of Interest Served as
More informationSoliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
More informationMicroangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del
Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del trattamento Vincenzo Montinaro U.O. Nefrologia Azienda Ospedaliera
More informationAn international consensus approach to the management of atypical hemolytic uremic syndrome in children
DOI 10.1007/s00467-015-3076-8 REVIEW An international consensus approach to the management of atypical hemolytic uremic syndrome in children Chantal Loirat & Fadi Fakhouri & Gema Ariceta & Nesrin Besbas
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationMedical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug
Medical Policy Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for informational purposes only and are not
More informationC3 Glomerulonephritis versus C3 Glomerulopathies?
Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 2016 C3 Glomerulonephritis versus C3 Glomerulopathies? T. Keefe Davis Washington University School of Medicine
More informationeculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd
eculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd 8 October 2010 (Amended 11 July 2011) The Scottish Medicines Consortium (SMC) has completed its
More informationISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CENTRO MARIO DI NEGRI RICERCHE INSTITUTE CLINICHE FOR PHARMACOLOGICAL PER LE MALATTIE RESEARCH RARE CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES
More informationTransforming Complement Therapeutics. June 2018
Transforming Complement Therapeutics June 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
More informationInitial management of TMA syndromes
Initial management of TMA syndromes Elie Azoulay, Saint-Louis Hospital, Medical Intensive Care Unit Paris Diderot Sorbonne University Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SA-PO546 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid,
More informationDynamics of complement activation in ahus and how to monitor eculizumab therapy
Regular Article CLINICAL TRIALS AND OBSERVATIONS Dynamics of complement activation in ahus and how to monitor eculizumab therapy Marina Noris, 1 Miriam Galbusera, 1 Sara Gastoldi, 1 Paolo Macor, 2 Federica
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More informationInternational PNH Interest Group Meeting Dec 8, 2017
International PNH Interest Group Meeting Dec 8, 2017 APL-2 is a C3 inhibitor APL-2 Subcutaneous for PNH, AIHA & CDN Intravitreal for GA Peptides of the APL-2 family bind to a pocket of C3 and inhibit activation*
More information3/31/2014 PNH. Jack Goldberg MD FACP. Clinical Professor of Medicine University of Pennsylvania
PNH Jack Goldberg MD FACP Clinical Professor of Medicine University of Pennsylvania 1 2 3 4 1 5 6 Historically Viewed as a Hemolytic Anemia Normal red blood cells are protected from complement attack by
More informationDIAGNOSTIC CHALLENGES IN THROMBOTIC MICROANGIOPATHIES
DIAGNOSTIC CHALLENGES IN THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 51 st ERA EDTA Congress, Amsterdam, the Netherlands, on 1 st June 2014 Chairperson
More informationHaemolytic Uraemic Syndrome and The ECUSTEC Trial
Haemolytic Uraemic Syndrome and The ECUSTEC Trial Dr Sally Johnson Consultant Paediatric Nephrologist Great North Children s Hospital 14 th October 2016 Haemolytic Uraemic Syndrome Commonest cause of intrinsic
More informationA Rational Approach to Evaluation of Thrombotic Microangiopathy
A Rational Approach to Evaluation of Thrombotic Microangiopathy An Algorithmic Approach C. Christopher Hook, MD for the Complement Alternative Pathway Thrombotic Micro- Angiopathy (CAP-TMA) Disease-Oriented
More informationCase 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016
Case 3 Lynn D. Cornell, M.D. Mayo Clinic, Rochester, MN Cornell.Lynn@mayo.edu USCAP Renal Case Conference March 13, 2016 ACCME/Disclosure Dr. Cornell has nothing to disclose Clinical history 57-year-old
More informationSoliris (eculizumab): Physician s guide to prescribing for patients with refractory generalised myasthenia gravis (gmg)
Soliris (eculizumab): Physician s guide to prescribing for patients with refractory generalised myasthenia gravis (gmg) CONTENTS PAGE WHAT IS SOLIRIS? SOLIRIS INDICATIONS IMPORTANT SAFETY INFORMATION SOLIRIS
More informationSoliris (eculizumab, rmc) Section 100 Restriction Criteria
Soliris (eculizumab, rmc) Section 100 Restriction Criteria A guide to initiation and ongoing access to (Section 100) funded Soliris for the treatment of patients with atypical Haemolytic Uraemic Syndrome
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Eculizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 5 References... 6 Effective Date... 8/15/2018 Next
More information